Newormics offers advanced microfluidic devices for high-throughput and high-content screening of small animal models and 3D tissue organoids. We also provide toxicology services and solutions.
New vivoChips launched!
vivoChip™-2x devices are now available for imaging L1 to L3 stage animals. Find out more...
See how vivoChip™ enables rapid immobilization and alignment of multiple worms for high resolution imaging
WHAT OUR USERS ARE SAYING
“The Newormics vivoCube and vivoChip system has revolutionized my imaging days! It’s easy to set up, fits nicely into our space, and is very user-friendly. And it’s so fast! I can image and score a full chip in about 40 minutes!”
Dr. Lotti Brose
Pierce-Shimomura Lab, University of Texas at Austin
“Newormics deliver on their promises, and have enabled our lab to perform high-throughput imaging in C. elegans. Their system is very easy to set up and use, the worms are very robustly oriented, and the chip is suitable for even high-resolution imaging!”
Saul Kato Lab, UCSF
“I found the L4-YA chip from Newormics extremely effective in immobilizing L4s and adults for live imaging even without supplementing the system with any anesthetics. The imaged worms also seemed to be in good condition when the imaging session was concluded...”
Conradt Lab, LMU Munich
“Newormics LLC...unveiled their microfluidic chips for easy immobilization and imaging of up to 5000 worms, proving yet again that you are only limited by your imagination! We already beta tested their dual chip that can immobilize up to 80 worms in tandem, across two sets of microfluidic channels, and it was awesome!”
Dr. Sangeetha Iyer
Director of Preclinical Development, Perlara
PRESENT CUSTOMERS INCLUDE
We are a team of innovators from Austin in the fields of microfluidics, life-science imaging, and chemical screening.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben Yakar began the research that has culminated in the launch of Newormics, LLC.
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at Newormics, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
Dr. Adam Laing is a molecular and cellular biologist educated at the University of Edinburgh, and leads the Research and Development activities of Newormics. He is responsible for testing and characterizing the new devices and imaging methods, and development of toxicology and drug screening assays in C. elegans as well as tissue organoids.
Shivang is a Biomedical Engineer, with sales & business acumen. He is heading our Sales & Marketing team and is responsible for customer relationship management, developing, maintaining and identifying KOLs, along with developing new product pricing strategies. He is also responsible for organizing marketing, media events, product promotional activities at conferences and B2B sales plans.
Dr. Lento is a serial COO/VPO executive for life science startups with broad skills in pharmaceuticals, medical devices, and diagnostics. With a unique background of equal parts government, public and private sector service, Dr. Lento’s holds a PhD in Biochemistry and additional credentials in Drug Evaluation, Pharmaceutical Sciences, and Corporate Governance.
DDNews features Newormics in their latest issue in a special report on drug screening
The research of Newormics is featured in a special report in the July 2019 issue of DDNews in an article titled “Phenotypic finery: Microscopy meets the molecular in the search for phenotypic impacts in drug screening”.